185 related articles for article (PubMed ID: 20926880)
1. Hepatotoxicity of agents used in the management of inflammatory bowel disease.
Khokhar OS; Lewis JH
Dig Dis; 2010; 28(3):508-18. PubMed ID: 20926880
[TBL] [Abstract][Full Text] [Related]
2. Hepatobiliary manifestations in inflammatory bowel disease: the gut, the drugs and the liver.
Rojas-Feria M; Castro M; Suárez E; Ampuero J; Romero-Gómez M
World J Gastroenterol; 2013 Nov; 19(42):7327-40. PubMed ID: 24259964
[TBL] [Abstract][Full Text] [Related]
3. Hepatic Complications of Inflammatory Bowel Disease.
Mahfouz M; Martin P; Carrion AF
Clin Liver Dis; 2019 May; 23(2):191-208. PubMed ID: 30947871
[TBL] [Abstract][Full Text] [Related]
4. Liver complications in inflammatory bowel diseases.
Wieser V; Gerner R; Moschen AR; Tilg H
Dig Dis; 2013; 31(2):233-8. PubMed ID: 24030232
[TBL] [Abstract][Full Text] [Related]
5. [Hepatobiliary Manifestation of Inflammatory Bowel Disease].
Seo KI; Kang SB
Korean J Gastroenterol; 2019 May; 73(5):248-259. PubMed ID: 31132831
[TBL] [Abstract][Full Text] [Related]
6. Liver and inflammatory bowel disease.
Nahon S; Cadranel JF; Chazouilleres O; Biour M; Jouannaud V; Marteau P
Gastroenterol Clin Biol; 2009 May; 33(5):370-81. PubMed ID: 19394180
[TBL] [Abstract][Full Text] [Related]
7. Liver-side of inflammatory bowel diseases: Hepatobiliary and drug-induced disorders.
Mazza S; Soro S; Verga MC; Elvo B; Ferretti F; Cereatti F; Drago A; Grassia R
World J Hepatol; 2021 Dec; 13(12):1828-1849. PubMed ID: 35069993
[TBL] [Abstract][Full Text] [Related]
8. Drug-induced liver injury in inflammatory bowel disease: 1-year prospective observational study.
Koller T; Galambosova M; Filakovska S; Kubincova M; Hlavaty T; Toth J; Krajcovicova A; Payer J
World J Gastroenterol; 2017 Jun; 23(22):4102-4111. PubMed ID: 28652663
[TBL] [Abstract][Full Text] [Related]
9. Risk of developing tuberculosis under anti-TNF treatment despite latent infection screening.
Jauregui-Amezaga A; Turon F; Ordás I; Gallego M; Feu F; Ricart E; Panés J
J Crohns Colitis; 2013 Apr; 7(3):208-12. PubMed ID: 22677117
[TBL] [Abstract][Full Text] [Related]
10. Risk of malignancies in patients with inflammatory bowel disease treated with thiopurines or anti-TNF alpha antibodies.
Beigel F; Steinborn A; Schnitzler F; Tillack C; Breiteneicher S; John JM; Van Steen K; Laubender RP; Göke B; Seiderer J; Brand S; Ochsenkühn T
Pharmacoepidemiol Drug Saf; 2014 Jul; 23(7):735-44. PubMed ID: 24788825
[TBL] [Abstract][Full Text] [Related]
11. Dosing 6-thioguanine in inflammatory bowel disease: expert-based guidelines for daily practice.
Seinen ML; van Asseldonk DP; Mulder CJ; de Boer NK
J Gastrointestin Liver Dis; 2010 Sep; 19(3):291-4. PubMed ID: 20922194
[TBL] [Abstract][Full Text] [Related]
12. Hepatobiliary manifestations of inflammatory bowel disease.
Yarur AJ; Czul F; Levy C
Inflamm Bowel Dis; 2014 Sep; 20(9):1655-67. PubMed ID: 24874461
[TBL] [Abstract][Full Text] [Related]
13. Liver diseases associated with anti-tumor necrosis factor-alpha (TNF-α) use for inflammatory bowel disease.
Coffin CS; Fraser HF; Panaccione R; Ghosh S
Inflamm Bowel Dis; 2011 Jan; 17(1):479-84. PubMed ID: 20848520
[TBL] [Abstract][Full Text] [Related]
14. Use of IBD Drugs in Patients With Hepatobiliary Comorbidities: Tips and Tricks.
Massironi S; Pirola L; Mulinacci G; Ciaccio A; Viganò C; Palermo A; Zilli A; Invernizzi P; Danese S
Inflamm Bowel Dis; 2023 Sep; 29(9):1477-1487. PubMed ID: 36040402
[TBL] [Abstract][Full Text] [Related]
15. Gastrointestinal and liver adverse effects of drugs used for treating IBD.
Rogler G
Best Pract Res Clin Gastroenterol; 2010 Apr; 24(2):157-65. PubMed ID: 20227029
[TBL] [Abstract][Full Text] [Related]
16. Incidence, management, and course of cancer in patients with inflammatory bowel disease.
Algaba A; Guerra I; Marín-Jiménez I; Quintanilla E; López-Serrano P; García-Sánchez MC; Casis B; Taxonera C; Moral I; Chaparro M; Martín-Rodríguez D; Martín-Arranz MD; Manceñido N; Menchén L; López-Sanromán A; Castaño Á; Bermejo F
J Crohns Colitis; 2015 Apr; 9(4):326-33. PubMed ID: 25687203
[TBL] [Abstract][Full Text] [Related]
17. Immune-mediated inflammatory reactions and tumors as skin side effects of inflammatory bowel disease therapy.
Marzano AV; Borghi A; Meroni PL; Crosti C; Cugno M
Autoimmunity; 2014 May; 47(3):146-53. PubMed ID: 24437626
[TBL] [Abstract][Full Text] [Related]
18. The impact of immunosuppressive therapy on QuantiFERON and tuberculin skin test for screening of latent tuberculosis in patients with inflammatory bowel disease scheduled for anti-TNF therapy.
Mantzaris GJ; Tsironikos D; Tzanetakou X; Grispou E; Karatzas P; Kalogeropoulos I; Papamichael K
Scand J Gastroenterol; 2015; 50(12):1451-5. PubMed ID: 26139305
[TBL] [Abstract][Full Text] [Related]
19. Serum Concentration of Anti-TNF Antibodies, Adverse Effects and Quality of Life in Patients with Inflammatory Bowel Disease in Remission on Maintenance Treatment.
Brandse JF; Vos LM; Jansen J; Schakel T; Ponsioen CI; van den Brink GR; D'Haens GR; Löwenberg M
J Crohns Colitis; 2015 Nov; 9(11):973-81. PubMed ID: 26116557
[TBL] [Abstract][Full Text] [Related]
20. Induction of psoriasis with anti-TNF agents in patients with inflammatory bowel disease: a report of 21 cases.
Guerra I; Algaba A; Pérez-Calle JL; Chaparro M; Marín-Jiménez I; García-Castellanos R; González-Lama Y; López-Sanromán A; Manceñido N; Martínez-Montiel P; Quintanilla E; Taxonera C; Villafruela M; Romero-Maté A; López-Serrano P; Gisbert JP; Bermejo F
J Crohns Colitis; 2012 Jun; 6(5):518-23. PubMed ID: 22398059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
